On December 18, 2008, Akatsuka, Hidenori; Sugama, Hiroshi; Awai, Nobumasa; Kawaguchi, Takayuki; Takahashi, Yoichi; Iijima, Toru; Shen, Jingkang; Xia, Guangxin; Xie, Jianshu published a patent.Recommanded Product: 3-Chloro-5-hydroxy-4-methoxybenzaldehyde The title of the patent was Preparation of morpholine derivatives as renin inhibitors. And the patent contained the following:
The title compounds I [R1 = alkyl (substituted with a group selected from (un)substituted alkoxy, OH, halo, etc.), (un)substituted aryl, (un)substituted heterocyclic group, etc.; R2 = alkyl (substituted with a group selected from (un)substituted alkoxy, OH, halo, etc.), (un)substituted aryl, (un)substituted heterocyclic group, etc.; T = methylene, carbonyl; R3 – R6 = H, (un)substituted carbamoyl, (un)substituted alkyl] are prepared Thus, (2R)-N-cyclopropyl-N-([4-(3-methoxypropoxy)-2-naphthyl]methyl)morpholine-2-carboxamide hydrochloride (II) was prepared in a multistep process starting from 4-hydroxy-2-naphthalenecarboxylic acid. II showed IC50 value of 30.2 nM against human renin. The experimental process involved the reaction of 3-Chloro-5-hydroxy-4-methoxybenzaldehyde(cas: 54246-06-9).Recommanded Product: 3-Chloro-5-hydroxy-4-methoxybenzaldehyde
The Article related to morpholine derivative preparation renin inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Oxazines (Including Morpholine) and other aspects.Recommanded Product: 3-Chloro-5-hydroxy-4-methoxybenzaldehyde
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics